NIH awards $5.8 million for development of next-generation H7N9 vaccine
EpiVax, Inc., a vaccine development and immune engineering company based in Providence, R.I., yesterday announced it is part of collaboration supported by a $5.8 million award from the National Institutes of Health (NIH) to develop a new type of vaccine against H7N9 avian influenza.